These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2479383)

  • 1. Interaction of arabinosyl nucleotides in K562 human leukemia cells.
    Gandhi V; Plunkett W
    Biochem Pharmacol; 1989 Oct; 38(20):3551-8. PubMed ID: 2479383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
    Gandhi V; Plunkett W
    Cancer Res; 1988 Jan; 48(2):329-34. PubMed ID: 3335008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
    Gandhi V; Plunkett W
    Cancer Chemother Pharmacol; 1992; 31(1):11-7. PubMed ID: 1458554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.
    Verhoef V; Fridland A
    Cancer Res; 1985 Aug; 45(8):3646-50. PubMed ID: 2410098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy.
    Gandhi V; Nowak B; Keating MJ; Plunkett W
    Blood; 1989 Nov; 74(6):2070-5. PubMed ID: 2478221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF; Huang P; Plunkett W; Gandhi V
    Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides.
    Gandhi V; Plunkett W
    Cancer Res; 1990 Jun; 50(12):3675-80. PubMed ID: 2340517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential modulation of 1-beta-D-arabinofuranosylcytosine metabolism by hydroxyurea in human leukemic cell lines.
    Kubota M; Takimoto T; Tanizawa A; Akiyama Y; Mikawa H
    Biochem Pharmacol; 1988 May; 37(9):1745-9. PubMed ID: 2454114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage.
    Sampath D; Plunkett W
    Cancer Res; 2000 Nov; 60(22):6408-15. PubMed ID: 11103806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical modulation of arabinosylcytosine for therapy of leukemias.
    Gandhi V; Estey E; Keating MJ; Plunkett W
    Leuk Lymphoma; 1993; 10 Suppl():109-14. PubMed ID: 8481660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular and clinical pharmacology of fludarabine.
    Gandhi V; Plunkett W
    Clin Pharmacokinet; 2002; 41(2):93-103. PubMed ID: 11888330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deoxyguanosine enhancement of cytarabine nucleotide accumulation in human leukemia cells.
    Akman SA; Ross DD; Joneckis CC; Fox BM; Bachur NR
    Cancer Treat Rep; 1985; 69(7-8):851-7. PubMed ID: 4016794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
    Kemena A; Gandhi V; Shewach DS; Keating M; Plunkett W
    Cancer Chemother Pharmacol; 1992; 31(3):193-9. PubMed ID: 1464155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
    Abe I; Saito S; Hori K; Suzuki M; Sato H
    Cancer Res; 1982 Jul; 42(7):2846-51. PubMed ID: 7083175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
    Gandhi V; Kemena A; Keating MJ; Plunkett W
    Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
    Danhauser L; Plunkett W; Liliemark J; Gandhi V; Iacoboni S; Keating M
    Leukemia; 1987 Sep; 1(9):638-43. PubMed ID: 3478543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation of cytosine arabinoside-5'-triphosphate in cultured human leukemic cell lines correlates with nucleoside transport capacity.
    Tanaka M; Yoshida S
    Jpn J Cancer Res; 1987 Aug; 78(8):851-7. PubMed ID: 3115933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic inhibition of human leukemia cell growth by deoxyguanosine and 1-beta-D-arabinofuranosylcytosine.
    Akman SA; Ross DD; Joneckis CC; Fox BM; Bachur NR
    Biochem Pharmacol; 1984 Apr; 33(7):1059-63. PubMed ID: 6712715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.